þ | ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2006 |
o | TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to |
Item 1-3 | ||||||||
Item 4 | ||||||||
SIGNATURES |
INCOME |
||||
Contribution Company Matching (co. stock) |
$ | 132,231 | ||
Contribution Participant 401(k) |
261,716 | |||
Investment Earnings |
125,860 | |||
Cash Value of Surrendered Insurance |
0 | |||
Realized Gain From Asset Sale |
0 | |||
Insurance Premium Refunds |
0 | |||
Other Income Rollovers |
104,907 | |||
Unrealized Appreciation of Assets |
0 | |||
Total Income |
$ | 624,714 | ||
EXPENSES |
||||
Life Insurance Premiums Paid |
$ | 0 | ||
Payments to Participants |
53,808 | |||
Bank Charges |
0 | |||
Brokerage Fees |
0 | |||
Administration Expenses Paid By the Trust |
0 | |||
Other Miscellaneous Expenses |
25 | |||
Total Expenses |
$ | 53,833 | ||
Income Over Expenses |
$ | 570,881 | ||
Assets At The Beginning Of The Plan Year |
673,405 | |||
Assets At The End Of The Plan Year |
$ | 1,244,286 | ||
As of | As of | |||||||
January 1, 2006 | December 31, 2006 | |||||||
ASSETS |
||||||||
Cash (Interest Bearing) |
$ | 94,819 | $ | 127,183 | ||||
Contribution Receivable (Co. Match) |
74,910 | 31,138 | ||||||
Contribution Receivable (401-K) |
0 | 13,595 | ||||||
Government Securities |
0 | 0 | ||||||
Mutual Funds |
474,418 | 787,983 | ||||||
Corporate Stocks & Bonds (Employer Stock) |
0 | 212,126 | ||||||
Real Estate and Mortgages |
0 | 0 | ||||||
Depreciable Buildings/Property |
0 | 0 | ||||||
Participant Loans |
29,258 | 72,261 | ||||||
Other Assets |
0 | 0 | ||||||
Total Assets |
$ | 673,405 | $ | 1,244,286 | ||||
LIABILITIES |
||||||||
Payables |
0 | 0 | ||||||
Acquisition Indebtedness |
0 | 0 | ||||||
Other Liabilities |
0 | 0 | ||||||
Total Liabilities |
$ | 0 | $ | 0 | ||||
NET ASSETS (Assets Less Liabilities) |
$ | 673,405 | $ | 1,244,286 | ||||
SPECTRUM PHARMACEUTICALS, INC. 401(K) PLAN |
||||
By: | Spectrum Pharmaceuticals, Inc. | |||
By: | /s/ Rajesh C. Shrotriya, M.D. | |||
Rajesh C. Shrotriya, M.D. | ||||
Chairman, Chief Executive Officer and President |